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Denervated muscles undergo fibrillations due to spontaneous activation of voltage-gated sodium (Na+) channels generating
action potentials. Fibrillations also occur in patients with amyotrophic lateral sclerosis (ALS). Riluzole, the only approved drug
for ALS treatment, blocks voltage-gated Na+ channels, but its effects on muscle Na+ channels and fibrillations are yet poorly
characterized. Using patch-clamp technique, we studied riluzole effect on Na+ channels in cultured myotubes from ALS patients.
Needle electromyography was used to study fibrillation potentials (Fibs) in ALS patients during riluzole treatment and after one
week of suspension. Patients were clinically characterized in all recording sessions. In myotubes, riluzole (1 𝜇M, a therapeutic
concentration) reduced Na+ current by 20%. The rate of rise and amplitude of spikes evoked by depolarizing stimuli were also
reduced. Fibs were detected in all patients tested during riluzole treatment and riluzole washout had no univocal effect. Our study
indicates that, in human myotubes, riluzole partially blocks Na+ currents and affects action potentials but does not prevent firing.
In line with this in vitro finding, muscle Fibs in ALS patients appear to be largely unaffected by riluzole.
1. Introduction
The current criteria for diagnosis of amyotrophic lateral scle-
rosis (ALS) require neurophysiological evidences of ongoing
denervation, defined by fibrillation potentials (Fibs) or posi-
tive sharpwaves, and of chronic partial reinnervation, involv-
ing enlarged, unstable motor units with a reduced interfer-
ence pattern [1]. Fibs are detected as long as denervation-
reinnervation processes take place [2], and their assessment is
considered a sensitivemethod to evaluate disease progression
and a useful research tool (see, for instance, [3]). At later
stages of disease they fade owing to replacement of muscle
fibres with fibrous tissue.
In mammalian denervated muscle fibres, fibrillations
arise because spontaneous activation of voltage-gated Na+
(NaV) channels triggers action potentials and contractions.
Accordingly, only NaV channel blockers stop fibrillations in
vitro [4]. In vivo, clinically used doses of lidocaine blocked
Fibs in denervated rats [5]. Disappearance of Fibs has been
reported in one ALS patient receiving fentanyl and propofol
during surgery [6], two anaesthetics that block NaV channels
[7, 8].
Riluzole is a well-established blocker of neuronal NaV
channels, but it also affects other channels in nonneu-
ronal tissues [9], for instance, muscle acetylcholine recep-
tor channels [9–12]. Riluzole also causes a mild block of
recombinant and native muscular voltage-gated Na+ current
(𝐼Na) [10, 13], although at concentrations higher than those
attained in patients’ plasma [9]. Inmyotubes, riluzole reduces
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the frequency of (rarely occurring) spontaneous contractions
[13]. Given these premises, riluzole might affect Fibs in ALS
patients, but this point has received little attention to date,
even if riluzole is the only approved drug for ALS treatment
[14]. Therefore, we undertook a study of riluzole action on
Fibs, aimed at filling this gap.
Detection of Fibs in patients requires needle electromyo-
graphy with uncomfortable multiple insertions. Thus the
study was started in vitro. Human muscle satellite cells can
be cultured in vitro in the absence of nerve, and myotubes
adequately represent denervated muscle fibres [15]. More-
over, satellite cells in vitro preserve traces of their in vivo
environment [16] including denervation-induced alterations
[17]. Satellite cells derived from ALS patients display a
reduced myogenic potential [18] but form multinucleated
myotubes (ALS myotubes; [11]). As commonly observed for
primary human myotubes [19–21], ALS myotubes do not
contract spontaneously. In the context of NaV channels, both
denervated muscle fibres and cultured myotubes express
NaV1.5 channels in addition to NaV1.4, the only form present
in innervated muscle fibres [22, 23]. Thus, ALS myotubes
provide a valuable experimental model with functional prop-
erties conditioned by donor health status. We therefore first
evaluated the effect of riluzole on muscle 𝐼Na and action
potentials in vitro and then verified our conclusions in vivo,
in a group of patients.
In ALS myotubes, riluzole affected the amplitude and
voltage dependence of 𝐼Na. As a consequence, spike amplitude
and rate of rise were reduced, but action potential firing was
not suppressed, suggesting that riluzole would not prevent
muscle fibrillations. Indeed, Fibs were routinely detected
during riluzole administration in ALS patients and brief
suspension of the treatment had no univocal effects on Fibs
frequency. All our data suggest that riluzole, in spite of
partially blocking muscle NaV channels, does not interfere
with muscle Fibs.
2. Materials and Methods
2.1. Cell Culture. Humanmyotubes were grown from satellite
cells derived from muscle biopsies performed at the ALS
Centre of Policlinico Umberto I, Sapienza University. All
patients gave written informed consent to use part of the
biopsy material for the research project entitled “Study of
Nicotinic Acetylcholine Receptor in Muscle Tissue of ALS
Patients,” approved by the Human Subjects Ethical Com-
mittee of Policlinico Umberto I. Satellite cells were obtained
immediately after biopsy as described [11, 12]. Frozen aliquots
were thawed for the present study and propagated as pre-
viously reported [11, 12]. Differentiation was induced at
50% confluence by switching to low-serum differentiating
medium (Dulbecco’s minimum essential medium plus 2%
horse serum and penicillin/streptomycin). Experiments were
performed 3 to 8 days after medium switch.
2.2. Patch-Clamp Recordings and Data Analysis. Whole-cell
patch-clamp recordings weremade at room temperature (23–
27∘C) using an Axopatch 200B amplifier (Molecular Devices,
Union City, CA, USA), driven by pClamp 9 (Molecular
Devices). Cells were continuously superfused using a gravity-
driven fast exchanger perfusion system (RSC-200, Bio-Logic,
France). External solution contained (mM) 140NaCl, 2.8 KCl,
2 CaCl
2
, 2 MgCl
2
, 10 HEPES-NaOH, and 10 glucose, pH 7.3.
Tetrodotoxin (TTX) and riluzole were added as indicated.
In some experiments, addition of 4-aminopyridine (2mM)
to block voltage-gated K+ channels did not affect 𝐼Na. Patch
pipettes (2–5MΩ) contained (mM) 130 CsCl, 10 NaCl, 5
BAPTA, 10 HEPES-KOH, 2 Mg-ATP, and 2 MgCl
2
, pH 7.3.
To record action potentials, KCl was used instead of CsCl.
All salts were from Sigma Italia (Milano, Italy). Recordings
were considered only if patch series resistance was less than
8MΩ and compensated by 95–99%. Riluzole-induced shifts
of activation and inactivation curves were unaltered if voltage
drop over uncompensated access resistance (𝑅
𝑈
) was kept
into account correcting the test potential (𝑉
𝑚
) as𝑉Corr = 𝑉𝑚−
𝑅
𝑈
∗ 𝐼Na and using 𝑉Corr in data analysis.
Current-voltage curves were obtained applying mem-
brane potential steps (5ms at 1 s interval) in 5mV increments
from −65mV to +60mV, from a steady holding potential of
−80mV. Fast inactivation curve was obtained using a two-
pulse protocol: prepulse potential (20ms) was changed from
−140mV to −15mV in 5mV increments, followed by a test
pulse to −10mV (5ms at 1 s interval), as previously done in
human muscle fibres [24]. Data were filtered at 5 kHz and
digitized at 50 kHz.
Current reversal potential (𝐸Na), estimated from plot of
peak 𝐼Na versus 𝑉𝑚, was 64 ± 1mV (𝑛 = 30), as predicted by
Nernst equation (66mV). Conductancewas calculated as𝐺 =
𝐼Na/(𝑉𝑚 − 𝐸Na) and normalized to the maximal value 𝐺max.
Values of 𝐺/𝐺max were then fitted with Boltzmann equation:
𝐺
𝐺max
=
1
[1 + 𝑒(𝑉−𝑉𝐴)/𝑘𝐴]
, (1)
where 𝑉
𝐴
is the potential at which conductance is half of
maximal value and 𝑘
𝐴
is the slope factor. Fast inactivation
relationships were constructed plotting current amplitude 𝐼,
normalized to maximal value 𝐼max, versus prepulse potentials
and fitting a Boltzmann equation to data points:
𝐼
𝐼max
=
1
[1 + 𝑒(𝑉−𝑉𝐼)/𝑘𝐼]
, (2)
where 𝑉
𝐼
is the potential at which current is half of maximal
value and 𝑘
𝐼
is the slope factor.
Action potentials were recorded under current clamp
conditions using stimuli of increasing amplitude (from 0.2
to 1 nA) at 1 s intervals. Phase plots, representing changes
in membrane potential with time (i.e., the first derivative of
membrane potential) versus the value of membrane potential
at the corresponding time, were built for each action potential
[25].
Results are given as mean ± SEM. Two data sets were
considered statistically different when 𝑃 < 0.05 by ANOVA
or Student’s paired 𝑡-test.
2.3. Patient Selection, Clinical Assessment, and Electromyogra-
phy Recordings. Eleven patients (6 females) with probable or
definite ALS according to El Escorial criteria were recruited
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Table 1: Patients characteristics.
Patient
(sex)
Age
(years)
Disease
duration
(months)
Clinical
onset
+Riluzole −Riluzole
𝑁Fibs
MRC right
lower limb
CMAP peroneal
nerve (mV)
𝑁Fibs
MRC right
lower limb
CMAP peroneal
nerve (mV)
1 (M) 55 34 Spinal 81.3 (88, 80, 76) 19 2.6 24.7 (28, 30, 16) 20 2.5
2 (F) 53 24 Spinal 94.7 (100, 90, 94) 21 2.8 146.7 (145, 140, 155) 20 2.9
3 (F) 53 23 Spinal 133.3 (148, 140, 112) 21 3.1 73.3 (70, 70, 80) 21 3.0
4 (M) 71 36 Spinal 126.6 (115, 127, 138) 12 0.10 153.3 (158, 140, 162) 12 0.14
5 (M) 56 55 Spinal 60 (85, 56, 39) 18 1.8 48.3 (43, 35, 67) 18 1.7
6 (F) 61 30 Spinal 106.7 (105, 102, 113) 25 3.8 124.7 (118, 128, 128) 25 3.9
7 (F) 51 19 Spinal 63.3 (55, 47, 88) 26 4.0 48.3 (64, 49, 32) 26 4.2
8 (M) 58 16 Bulbar 27 (30, 25, 26) 31 9.7 32.3 (34, 38, 25) 31 9.8
9 (F) 75 27 Bulbar 32.7 (28, 37, 33) 27 9.8 36 (38, 32, 38) 27 9.6
10 (F) 63 10 Spinal 82 (78, 88, 80) 30 8.9 40 (45, 40, 35) 30 8.7
11 (M) 50 13 Spinal 106.7 (101, 100, 119) 29 7.7 33.3 (36, 35, 29) 29 7.6
Demographic and clinical characteristics of the 11 patients with ALS evaluated during riluzole treatment (+Riluzole) and after 1-week withdrawal (−Riluzole).
𝑁Fibs: average number (number in each insertion) of fibrillation potentials (Fibs); MRC lower limbs: Medical Research Council score for lower limbs; CMAP:
amplitude of peroneal compound muscle action potential. Number of Fibs is not significantly affected by riluzole treatment (𝑃 = 0.69 by Wilcoxon test).
and analyzed at the ALS centre of Policlinico Umberto
I, Sapienza University (Table 1). Inclusion criteria were as
follows: male or female subjects older than 18 years; disease
duration lower than 60 months; treatment with riluzole for
at least 3 months before the study; no history of alcohol
or substance abuse; no other neuromuscular disorders and
diabetesmellitus; nomarked lower limbs spasticity (>2 on the
modified Ashworth scale); absence of psychiatric disorders
or cognitive impairment at first evaluation; no concomitant
therapy with psychoactive drugs.
Muscle strength of lower limbs was assessed with the
Medical Research Council (MRC) score for muscle strength
[26], an ordinal scale ranging from 0 (absence of movement)
to 5 (normal contraction against full resistance) that quanti-
fies muscle weakness in isolated muscles or muscle groups.
Five muscle groups in lower limbs are tested: hip flexors,
knee extensors, knee flexors, ankle plantar flexors, and ankle
dorsiflexors.
An electromyographic instrument (System Plus Evolu-
tion 1.04.0104) employing a one-channelmontage (sensitivity
50 𝜇V/division; low frequency filter 20Hz; high frequency
filter 5 KHz) was used to detect electrical activity. During
the electrophysiological procedures, skin temperature was
maintained between 31 and 34∘C.
Monopolar needle electrodes were utilized to detect
the insertional activity. Needle electromyographic signals
were recorded from the right anterior tibialis muscle at a
site approximating the demarcation between the proximal
one-third and distal two-thirds of the muscle [27]. Three
consecutive needle insertions (10 s each) with the same depth
of insertion of needle (1.5 cm) per session were performed in
all patients. A reference landmark by indelible pen allowed
recording at the same muscle site in the second session. The
number of Fibs discharges in each recording was counted
manually.
Right tibialis anterior compound muscle action potential
(CMAP) was evoked by peroneal nerve stimulation. The
stimulating cathode was placed at the posterior-lateral area
of the fibular head. The point for the recording surface
electrodes was placed 8 cm from the cathode over the tibialis
anterior. Reference electrodes were located over the tendons
of the tibialis anterior. The latency of CMAP was measured
from the stimulus artefact to the onset point, and the ampli-
tude was determined from baseline to the highest negative
peak [28].
Recordings were performed before and after a one-week
suspension of riluzole treatment. Data were compared using
the Wilcoxon signed rank test. Results were considered to be
significantly different when 𝑃 < 0.05.
The study was conducted in accordance with the guide-
lines of the Declaration of Helsinki.
3. Results
3.1. Effect of Riluzole on 𝐼Na in ALS Myotubes. Voltage-gated
Na+ current (𝐼Na) was recorded in all multinucleated myo-
tubes (3–8 days differentiation) examined. Current density
was 0.27 ± 0.03 nA/pF (𝑛 = 22) with the largest current
obtained at test potentials of −20 to 0mV (Figure 1(a)). Cur-
rent was reduced to 28 ± 3% (𝑛 = 10) of control value by TTX
(1 𝜇M, not shown), as expected in myotubes which express a
mixture of NaV1.4 and NaV1.5 channels, with half-inhibitory
TTX concentration of 10 nMand 3𝜇M, respectively [23], thus
confirming that recorded signals were bona fideNa+ currents.
Applying riluzole 1𝜇M, a clinically relevant concentration
[9], 30 s before stimulation, total 𝐼Na amplitude was 79 ± 2%
(𝑛 = 22) of untreated value (Figure 1(a)). In all cells tested,
activation and steady-state fast inactivation curves were
modified in the presence of riluzole.The activation curve had
a depolarizing shift (Figure 1(b)), with a mean increase for𝑉
𝐴
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Figure 1: Effect of riluzole on voltage-gated sodium currents. (a) Family of currents evoked by test pulses from −65mV to +60mV in
5mV increments (top traces), from a steady holding potential of −80mV, under control conditions or in the presence of riluzole (1𝜇M, 30 s
pretreatment). Peak current-voltage plot was constructed for the same recordings. (b) Activation curves obtained in the absence or presence
of riluzole, with the best fitting Boltzmann curves (black lines). Riluzole induced a depolarizing shift of the curve of about 3mV and 𝑘
𝐴
was
slightly but significantly increased. (c) Typical currents evoked by fast inactivation two-pulse protocol (top traces): a prepulse (20ms) from
−140mV to −15mV in 5mV increments followed by a test pulse to −10mV.Holding potential between recordings was −80mV. (d) Steady-state
fast inactivation curves had a hyperpolarizing shift, accompanied by a decrease of 𝑘
𝐼
. Symbols as indicated.
of 2.4 ± 0.3mV (𝑛 = 22, 𝑃 < 0.0004), and 𝑘
𝐴
was significantly
increased by 0.6 ± 0.1mV (𝑛 = 22, 𝑃 = 0.0004). Steady-state
fast inactivation curves had a hyperpolarizing shift (Figures
1(c) and 1(d)), with 𝑉
𝐼
decreasing by −8.7 ± 1.5mV (𝑛 = 7,
𝑃 = 0.001) and 𝑘
𝐼
by −3.5 ± 0.5mV (𝑛 = 7; 𝑃 = 0.0004).
3.2. Effect of Riluzole on Action Potentials. These riluzole-
induced shifts in activation and fast inactivation of 𝐼Na might
reverberate on action potential generation, reducing spike
amplitude (because of enhanced fast inactivation) and rate
of rise (due to reduced current amplitude). Small thresh-
old modifications due to the depolarizing shift of channel
activation were also expected. We therefore recorded action
potentials evoked by depolarizing currents of increasing
amplitude, using current clamp mode. In these myotubes,
membrane resting potential ranged between−40 and−25mV,
so hyperpolarization (to −89.0 ± 1.4mV, 𝑛 = 5) was required
to elicit action potentials. Depolarizing currents evoked
overshooting spikes in all myotubes tested, but amplitude
and rate of rise were reduced in the presence of riluzole
(Figure 2(a)). In the five myotubes tested, spike peak and
rate of rise were 29.7 ± 5.1mV and 119 ± 18mVms−1 under
control conditions and 21.3 ± 5.3mV and 89 ± 17mVms−1, in
the presence of riluzole (𝑃 ≤ 0.002 by paired Student’s 𝑡-test).
Action potential peak was delayed by 1.8 ± 0.7ms (𝑛 = 5;
𝑃 = 0.03). Furthermore, phase plots showed a small shift in
threshold potential, compatible with the depolarizing shift of
𝑉
𝐴
measured in each myotube (Figure 2(b)).
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Figure 2: Effect of riluzole on action potentials. Action potentials (a) elicited by a depolarizing current (top, 0.2 nA) and phase plot (b) of the
same traces. In the presence of riluzole (grey traces), both peak depolarization and rate of rise were reduced, in spite of unchanged holding
potential. Magnification of the inflection point (inset) discloses a depolarizing shift of the threshold of spike onset. The inflection point
represents the threshold potential, the positive peak corresponds to the maximal depolarization rate, and the largest value on the horizontal
axis is the spike peak value.
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Figure 3: Fibrillation potentials in an ALS patient before and after
riluzole suspension. Electromyography recordings performed in
one ALS patient during riluzole therapy (top trace) and after a 1-
week suspension of treatment (bottom trace). Notice that fibrillation
potentials showed no significant change.
Thus, riluzole reduces excitability of myogenic cells but
does not prevent action potential generation in response to
depolarizing stimuli, suggesting that it might be ineffective
on muscle fibrillations. We therefore investigated this point
directly.
3.3. Human Studies. All patients were treated with riluzole
(average treatment duration, 13.8 months) and suspended
treatment for one week for this study. This time is adequate
for riluzole washout, estimated to be complete within about
40 hours of withdrawal [29]. Multiple Fibs were detected in
all patients’ anterior tibialis muscle (Figure 3). Across the 3
insertions performed, their number had small fluctuations
in all but Patients 5 and 7, which suggests that variability
due to needle position is limited. In the second recording
session, oneweek after riluzole withdrawal, clinical status and
CMAP amplitude were unchanged for all patients (Table 1),
indicating that no relevant alteration in muscle innervation
took place. Fibs continued to be present in all patients,
and variability between insertions did not change. When
compared to the first recording session, the total number of
Fibs changed by less than 25% in six patients; in the other
5, changes ranged between a 55% increase (Patient 2) and a
70% decrease (Patient 1). Overall, there was no statistically
significant variation in the number of Fibs upon riluzole
treatment suspension (𝑃 = 0.69) (Table 1). The effect of
riluzole withdrawal showed no correlation with patients’ age,
sex, disease duration, or Fibs frequency at baseline (data not
shown).
4. Discussion
In this paper we studied the effect of riluzole on voltage-
gated sodium channels in human myotubes and on Fibs in
ALS patients. In vitro, we show that riluzole at a therapeu-
tically used concentration reduces 𝐼Na and shifts the voltage
dependence of gating. As a consequence, action potentials
evoked by depolarizing currents have lower amplitude and
reduced rate of rise.These results clearly indicate that riluzole
acts on channels present on muscle fibres. The therapeutic
implications of this nonneuronal effect, if any, are presently
unknown. For instance, the documented partial block of
muscle NaV channels may result in dampened spontaneous
activations of these channels and limit Fibs occurrence in
patients’ denervated muscle fibres.
Here we report that Fibs were consistently recorded
during riluzole treatment in ALS patients, a clear indication
that riluzole does not suppress muscle fibrillations. We were
unable to detect univocal effects on Fibs upon riluzole with-
drawal in the group of patients considered. Likely, other
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factors influence the frequency of Fibs, an inherently ran-
dom process. Would a larger cohort of patients yield more
conclusive data? The in vitro findings here reported indicate
that riluzole has a small effect on action potential firing. Data
obtained in patients do not disclose even a trend in the change
of Fibs frequency upon riluzole withdrawal. Thus, extension
of the in vivo study to a larger number of patients appears
of little significance, also considering the discomfort of the
procedure and the burden of repeated hospital access for
heavily disabled patients.
None of the previous studies showing that NaV channel
blockers can suppress Fibs in vivo [5, 6] assessed the plasma
concentration of the drugs, so it is not possible to correlate
disappearance of Fibs with the extent of NaV channels
blockade. In organ cultures of ratmuscle, TTXprevented Fibs
when used at 1 𝜇M [4], which we show here to block a larger
fraction of 𝐼Na than riluzole at the concentration used. Thus,
it is likely that riluzole-induced block of muscle 𝐼Na is not
sufficient to prevent Fibs. The aforementioned studies [4–6]
report effects observed within minutes of drug application,
whereas our data were collected in patients routinely taking
riluzole or after a washout lasting one week, so that it cannot
be ruled out that adaptations to long-term presence/absence
of riluzole contribute to its inability to prevent Fibs in the
examined patients.
A reduced rate of rise of evoked action potentials under
riluzole, here reported for cultured myotubes, was also
observed in guinea pig cardiac Purkinje fibres [30] but not
in rat ventricular cardiomyocytes [31].
5. Conclusions
This study shows that riluzole at a typical clinical concentra-
tion partially blocks muscle NaV channels and dampens—
but does not abolish—the action potentials evoked by depo-
larizing stimuli in ALS myotubes. As suggested by in vitro
inability to fully suppress spikes, riluzole does not prevent
muscle Fibs in ALS patients, apparently having very limited
impact on this symptom. Therefore, the pattern of Fibs
disappearance during disease progression is unlikely to be
directly influenced by riluzole-induced block of muscle NaV
channels.
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